FDA OK's Long Term Use of Kidney Rejection Preventative
CTI Announces the FDA allows long term use of ISA247 in Isotechnika Phase 2b clinical program for the prevention of rejection following kidney transplantation
CINCINNATI, OH, October 22, 2007-CTI Clinical Trial and Consulting Services (CTI) announced that Isotechnika has received permission from the U.S. Food and Drug Administration (FDA) for the long term use of ISA247 in patients currently participating in Isotechnika’s Phase 2b kidney transplant (PROMISE) trial. Isotechnika previously announced that they had also received a “No Objection” Letter from Health Canada for the long term use of ISA247 in this trial.
With these announcements, patients involved in the PROMISE trial are allowed to remain on ISA247 through commercialization of the drug and beyond after completion of the 12 month trial. Patients choosing to remain on ISA247 therapy will continue to have safety and efficacy parameters monitored on an ongoing basis. Isotechnika believes that having patients continue to receive ISA247 therapy may contribute to an improved quality of life subsequent to transplantation.
The long-term data received from these patients will facilitate ISA247 achieving its commercial potential. CTI is managing the multicenter North American trial on behalf of Isotechnika.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
